India Immunoassay Market By Product (Reagents and Kits, Analyzers/Instruments, Software and Services), By Technology (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoro Immnoassay (FIA), Chemiluminescence Immunoassay (CLIA), Rapid Test, Others), By Indication (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Diseases, Autoimmune Diseases, Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

The Immunoassay Market in India was valued at USD 1.19 billion in 2024 and is projected to reach USD 1.70 billion by 2030, growing at a CAGR of 6.25% during the forecast period. This growth reflects the increasing reliance on immunoassay technologies as essential tools in clinical diagnostics and biomedical research.

Immunoassays are advanced biochemical tests that detect and quantify specific substances in complex biological samples using highly selective antigen-antibody interactions. Widely used in diagnostics and research, they play a crucial role in infectious disease testing, endocrinology, oncology, and autoimmune disorder diagnosis, making them essential in modern healthcare systems.

The immunoassay market in India is expanding due to the rising prevalence of chronic, infectious, and autoimmune diseases, increasing the demand for accurate, sensitive, and rapid diagnostic solutions. These tests support early disease detection, prognosis, and treatment monitoring, improving clinical outcomes.

A 2023 study in Bihar highlighted the effectiveness of Indirect Immunofluorescence (IIF) and Line Immunoassay (LIA) in diagnosing autoimmune diseases, particularly systemic lupus erythematosus. Technological advancements in automation, sensitivity, and specificity, along with improved accessibility, are further driving adoption across hospitals and laboratories, strengthening India’s diagnostic capabilities.

Key Market Drivers

High Sensitivity and Specificity of Immunoassays

• The high sensitivity and specificity of immunoassays are key drivers of adoption in Indian diagnostic laboratories, enabling detection of biomarkers at very low concentrations. This supports early diagnosis, reliable screening, and stronger clinical decision-making across infectious diseases, oncology, endocrinology, and routine testing.

• In oncology, accurate biomarker detection is critical for diagnosis, treatment selection, and monitoring. India’s National Cancer Registry Programme estimated 14,61,427 new cancer cases in 2022, increasing demand for precise and reproducible assays.

• The Government of India’s e-RaktKosh platform, used by 2800+ blood banks across 36 States and Union Territories, highlights the expansion of standardized and digitized laboratory systems, where consistent immunoassay performance is essential.

• High analytical performance reduces false results, improves clinician confidence, and supports timely intervention. As India strengthens diagnostic capacity and preventive screening, demand for sensitive and specific immunoassays will remain strong.

Technological Advancements in Immunoassay Instruments

• Technological advancements in immunoassay instruments are accelerating market growth in India, driven by the need for reliable, high-performance diagnostics. Modern systems offer high sensitivity, rapid turnaround, compact design, and better workflow integration, improving detection and efficiency.

• Automation and miniaturization are enhancing throughput, consistency, and space utilization, while also supporting research and advanced diagnostics.

• For example, Mindray’s chemiluminescence-based platforms and Serum Automation Line (SAL-6000 and SAL-9000) integrate chemistry and immunoassay systems for high-volume laboratories. This improves efficiency, optimizes space, and ensures reproducible results.

• Point-of-care immunoassays are expanding access in remote areas by enabling faster decisions and treatment initiation. Combined with government support, rising health awareness, and interest in personalized medicine, these innovations are strengthening the role of immunoassay instruments in India’s diagnostic ecosystem.

Increasing Prevalence of Chronic and Infectious Diseases

• The rising burden of chronic and infectious diseases in India, including cardiovascular conditions, diabetes, cancer, tuberculosis, and hepatitis, is significantly increasing demand for immunoassay diagnostics. These conditions require fast, accurate, and scalable testing for early detection and ongoing monitoring.

• Immunoassays provide reliable performance across multiple disease areas, making them essential in high-volume and time-sensitive healthcare settings.

• According to the National Library of Medicine, about 21% of India’s elderly population has at least one chronic disease, with hypertension and diabetes accounting for nearly 68% of cases, highlighting strong long-term demand for diagnostic testing.

• Improved healthcare infrastructure, rising awareness, and expansion of diagnostic centers are increasing access to advanced testing. India’s large population further drives the need for efficient and scalable diagnostic solutions, making immunoassays central to disease management and public health.

Increasing Incidence of Cancer

• The rising incidence of cancer in India is a major driver of the immunoassay market, as these tests are essential for biomarker detection, diagnosis, monitoring, and therapy selection.

• Growing population and expanding healthcare access are increasing demand for advanced diagnostics across hospitals and laboratories. Rising awareness of early detection is further boosting routine screening and use of immunoassays for timely diagnosis and follow-up.

• Government efforts to strengthen healthcare infrastructure and expand access to advanced technologies are supporting wider adoption. Additionally, the emergence of local manufacturers offering cost-effective solutions is improving affordability and accessibility.

• Together, increasing cancer burden, stronger screening practices, expanding healthcare capacity, and local manufacturing are driving immunoassay adoption in India, supporting better diagnostics and treatment outcomes.

Key Market Challenges

Stringent Regulatory Scenario for Approval of Immunoassays

• India’s stringent regulatory framework remains a major restraint on immunoassay market growth, as approval for new assays involves a rigorous and time-intensive review of clinical efficacy, safety, and quality. The CDSCO enforces these standards, which protect patients but often delay product commercialization.

• These prolonged approval timelines are especially problematic in a fast-changing disease environment, where demand for advanced diagnostic tools is rising. Delayed access to innovative immunoassays can affect diagnosis and treatment outcomes, while also reducing manufacturers’ ability to respond quickly to emerging healthcare needs.

• Regulatory compliance also increases operational costs, placing added pressure on manufacturers, particularly small and medium-sized companies that may struggle with the complexity and expense of approval requirements. Streamlining the process while preserving safety and efficacy standards is essential to support innovation, investment, and faster market access.

Complexity of Procedures

• The growth of immunoassay techniques in India is being constrained by procedural complexity, as many assays involve intricate protocols and require specialized expertise for accurate execution. This creates a significant barrier in settings where skilled personnel, technical training, and laboratory resources remain limited.

• Market expansion is further restricted by the lack of standardized procedures, the need for advanced laboratory infrastructure, and the time-consuming nature of many immunoassay tests, which reduces suitability for time-sensitive diagnostics. High costs for sophisticated reagents and equipment maintenance also limit broader adoption across healthcare facilities.

• Together, procedural complexity, infrastructure gaps, limited training, and cost burdens are slowing immunoassay adoption in India. Simplifying workflows, strengthening personnel training, and improving accessibility to efficient testing systems will be critical to unlocking the full diagnostic and therapeutic potential of immunoassays in the country.

Key Market Trends

Increased Patient Awareness

• Immunoassay testing in India is gaining momentum as patient awareness of advanced diagnostic techniques rises through health education programs, online platforms, and patient-doctor interactions. Because immunoassays deliver fast and accurate results, they are becoming a preferred option for diagnosing infectious diseases, endocrine disorders, and oncological conditions.

• Rising lifestyle diseases, especially diabetes and cardiovascular disorders, are further strengthening demand for immunoassays as patients increasingly value early, precise, and timely diagnosis for better treatment outcomes. This shift in patient behavior is expanding the role of immunoassay testing across routine and specialized diagnostic settings in India.

• Public and private sector initiatives are also supporting market growth. In March 2024, Fapon highlighted its commitment to India’s IVD industry at Medical Fair India 2024 in Mumbai by showcasing biomarkers, blockers, bulk reagents, assays, and instrument platforms tailored to evolving local healthcare needs and manufacturer requirements.

• Government efforts to improve healthcare infrastructure and expand access to advanced diagnostic services, including in rural areas, are accelerating adoption. Together, rising patient awareness, increasing lifestyle disease prevalence, industry innovation, and stronger healthcare accessibility are creating a favorable environment for sustained immunoassay market expansion in India.

Emerging Trend of Smartphone-Based Formats and Multiplex Bead Assays

• Smartphone-based immunoassay formats are emerging as a strong growth driver in India because they offer portability, affordability, rapid interpretation, and practical deployment in resource-constrained settings. Their ability to support real-time result analysis and smooth data sharing between healthcare professionals is transforming diagnostic accessibility and efficiency.

• Multiplex bead assays are also advancing the immunoassay market by enabling simultaneous detection of multiple analytes in a single sample, improving both efficiency and diagnostic accuracy. This is especially valuable for complex diseases such as autoimmune disorders and cancers, where multiple biomarkers are involved and more advanced testing tools are increasingly needed in India.

• The adoption of these technologies is further reinforced by government initiatives aimed at improving healthcare infrastructure and accessibility. By integrating smartphone-enabled diagnostics and multiplex testing capabilities, India is strengthening its position in rapid, accurate, and affordable immunoassay solutions while setting a new benchmark for modern diagnostic innovation.

Segmental Insights

Product Insights

Based on the product, Reagents and kits accounted for the largest market share in the India immunoassay market in 2023. This segment is projected to maintain its lead over the forecast period, driven by the high demand for immunoassay reagents and kits for diagnostic purposes. With the growing prevalence of infectious and autoimmune diseases, there is an increasing need for reliable and efficient immunoassay solutions. The approval and launch of novel immunoassay kits are expected to further support this segment's growth, providing more advanced and accurate diagnostic options.

On the other hand, the software and services segment is expected to grow at a steady compound annual growth rate (CAGR) over the forecast period. This can be attributed to the increased availability and high demand for cost-effective immunoassay services, especially in developing markets. For example, in June 2020, Sysmex Corporation began offering novel coronavirus (SARS-CoV-2) antibody lab assay services, addressing the urgent need for reliable testing during the pandemic. Overall, the India immunoassay market is poised for significant growth, driven by ongoing advancements in reagents, kits, software, and services that are crucial for accurate and timely diagnosis of various diseases.

Technology Insights

Based on technology, Enzyme Immunoassays (EIA) are expected to remain dominant in the India immunoassay market. This is primarily due to its extensive use in clinical diagnostics, drug monitoring, and pharmaceutical analysis. EIA stands out due to its remarkable accuracy, affordability, and ability to deliver rapid results, making it a preferred choice in the Indian medical landscape.

The versatility of EIA in detecting a wide range of diseases is another key factor contributing to its dominance. From infectious diseases to chronic diseases and even cancer, EIA has proven effective in diagnosing and monitoring a range of health conditions. This comprehensive disease detection capability further solidifies EIA as the technology of choice for healthcare professionals in India. With its widespread adoption and numerous benefits, the Enzyme Immunoassays technology continues to play a vital role in advancing medical diagnostics and improving patient care in India.

Download Free Sample Report

Regional Insights

The Western region of India, encompassing the vibrant cities of Mumbai and Pune, is currently dominating the immunoassay market nationwide. This remarkable feat can be attributed to the rapid growth of the healthcare sector in this region, which has seen a surge in advanced diagnostic facilities and the prevalence of chronic diseases. The region's robust ecosystem benefits from the presence of leading pharmaceutical companies and renowned research institutes, further bolstering its market share and solidifying its position as a key player in the field.

The healthcare sector in the Western region has witnessed significant advancements in recent years. The availability of state-of-the-art diagnostic facilities has contributed to accurate and timely detection of various diseases. This, in turn, has led to improved patient outcomes and a higher demand for immunoassay technologies. The region's proactive approach towards healthcare has attracted leading pharmaceutical companies to establish their presence here. Their collaborations with renowned research institutes have led to groundbreaking discoveries and innovations in immunoassays. This collaborative approach has not only enhanced the region's market share but also positioned it as a hub for cutting-edge research and development.

In addition, the Western region's strategic geographical location and well-developed infrastructure have played a crucial role in its dominance in the immunoassay market. The region's easy accessibility, coupled with efficient logistics, has enabled the seamless distribution of immunoassay products across the country. The Western region of India has emerged as a frontrunner in the immunoassay market, driven by the healthcare sector's remarkable growth, a strong ecosystem, and strategic advantages. With continuous advancements and collaborations, the region is poised to further expand its market share and solidify its position as a key player in the field.

Recent Developments

• In February 2025, Redcliffe Labs inaugurated a diagnostic laboratory in Jamshedpur, Jharkhand, expanding its footprint in the state to two advanced diagnostic labs and more than 50 collection centres. The company said the facility was launched to address the growing burden of non-communicable diseases and offers testing across biochemistry, haematology, immunoassays, clinical pathology, hormones, and serology. Redcliffe also stated that the lab can handle more than 10,000 samples a month, making the launch relevant to India’s immunoassay landscape because it expands local testing capacity rather than merely adding a collection point.

• In May 2025, Apollo Diagnostics launched its Digi-Smart Central Reference Laboratory in Chennai, a 45,000-square-foot fully automated facility that integrates clinical chemistry, immunoassay, serology, haematology, and haemostasis into a unified digital workflow. According to the company, the lab uses robotics, high-definition cameras, machine learning, and proprietary algorithms, and is designed to reduce turnaround time by 60 percent while processing more than 100,000 samples daily for India and Southeast Asia. This is significant for the immunoassay segment because immunoassay was built into a high-throughput reference-lab model aimed at faster, more scalable diagnostics.

• In September 2025, ICMR announced at India MedTech Expo 2025 that it had licensed nine cutting-edge medical technologies to industry partners under its Medical Innovations–Patent Mitra initiative, resulting in 17 licensing deals. The official release said those agreements covered infectious disease diagnostics, immunodiagnostics, and vaccine development, which directly places immunoassay-linked technologies within a commercialization pipeline tied to Indian industry. This development stands out as a collaboration-led innovation story because it connected publicly developed diagnostic technologies with industry partners for downstream deployment.

• In December 2025, City Imaging & Clinical Labs unveiled the VITROS 5600 Integrated System, which brings clinical chemistry and immunoassay testing onto one fully automated diagnostic platform. Express Healthcare reported that the system uses Dry Slide Technology for stable calibration and a MicroWell chemiluminescence method that improves sensitivity for hormone and immunoassay testing, while supporting up to 900 tests per hour and more than 160 assays. For India’s immunoassay market, this qualifies as a meaningful product deployment because it combines higher sensitivity, fewer repeat assays, and faster turnaround in routine lab operations.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott India Ltd.
• BioMérieux India Pvt. Ltd.
• Bio-Rad laboratories India Pvt.Ltd
• Becton Dickinson Pvt.Ltd
• Thermo Fisher Scientific India Pvt. Ltd.
• Danaher India (DHR Holding India Pvt. Ltd.)
• Siemens Healthcare Private Limited
• Randox Laboratories (India) Pvt. Ltd.
• Sysmex India Pvt. Ltd.

Report Scope:

In this report, the India Immunoassay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Immunoassay Market, By Product:

o   Reagents and Kits

o   Analyzers/Instruments

o   Software and Services

• India Immunoassay Market, By Technology:

o   Radioimmunoassay (RIA)

o   Enzyme Immunoassays (EIA)

o   Fluoro Immnoassay (FIA)

o   Chemiluminescence Immunoassay (CLIA)

o   Rapid Test

o   Others

• India Immunoassay Market, By Indication:

o   Therapeutic Drug Monitoring

o   Oncology

o   Cardiology

o   Endocrinology

o   Infectious Diseases

o   Autoimmune Diseases

o   Others

• India Immunoassay Market, By End User:

o   Hospitals & Clinics

o   Pharmaceutical & Biotechnology Companies

o   Academic & Research Institutions

o   Others

• India Immunoassay Market, By Region:

o   North

o   South

o   West

o   East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Immunoassay Market.

Available Customizations:

India Immunoassay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Immunoassay Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]